Discovering Tomorrow's Drugs:

How AI and JUMP-Cell Painting are Shaping Pharmaceutical Advances

Gain Insights Into:

  • The Fundamentals of Molecular Profiling
  • The Genesis and Mission of the JUMP-CP Consortium
  • The Role of AI Tools in Enhancing the Value of the JUMP-CP Dataset


Guest Speaker Insights:

  • Get Introduced to the JUMP-CP Consortium by its Catalyst, Dr. Anne Carpenter
  • Understand the Evolution and Potential of Cell Painting Assay from its Inventor


Join The Discussion On:

  • How AI Tools like the phenAID JUMP-CP Explorer Can Transform Drug Discovery

Join us for an engaging webinar that explores the groundbreaking impact of the JUMP-Cell Painting Consortium on drug discovery.

Learn about the data-driven approach that uses cellular imaging, image analysis, and data analytics to improve the pharmaceutical pipeline by better understanding the mechanism of action of potential therapeutics before clinical trials. Dive into the vast public dataset created to expand this image-based drug discovery strategy, which is now available for various applications like predicting compound activity and toxicity, matching drugs to diseases, and more.

We are thrilled to welcome Dr. Anne Carpenter from The Broad Institute as our guest speaker. As the inventor of the Cell Painting Assay and the driving force behind the JUMP-CP initiative, Dr. Carpenter will provide valuable insights into the consortium and its vision for the future of drug discovery.

During the webinar you will also hear about the PhenAID JUMP-CP Data Explorer, a user-friendly web application that helps navigate the JUMP-CP Cell Painting dataset. The JUMP-CP data explorer is part of the PhenAID platform, an AI-powered tool that combines high content screening images and molecular structures to enable tasks such as Mode of Action and biological property prediction, as well as  virtual screening.

Don't miss this opportunity to learn about the future of drug discovery with JUMP-CP and how the phenAID JUMP-CP Explorer is benefiting professionals in big pharma and academics working in the drug discovery field. Register now to secure your spot and unlock the potential of this innovative approach.


Meet our speakers:

Anne Carpenter, PhD
Institute Scientist, Imaging Platform Senior Director, Broad Institute of Harvard and MIT

Dr. Carpenter is an Institute Scientist at the Broad Institute of Harvard and MIT. Her research group develops algorithms and strategies for large-scale experiments involving images. The team’s open-source CellProfiler software is used by thousands of biologists worldwide and their Cell Painting assay has been adopted throughout the pharma industry to accelerate drug discovery. She led the JUMP Cell Painting Consortium to build the first and largest public database of Cell Painting images of chemical and genetic perturbations.

Her PhD is in cell biology from the University of Illinois, Urbana-Champaign and her postdoc in high-throughput image analysis was at the Whitehead Institute for Biomedical Research and MIT’s CSAIL (Computer Sciences/Artificial Intelligence Laboratory). Carpenter has been named an NSF CAREER awardee, an NIH MIRA awardee, a Massachusetts Academy of Sciences fellow (its youngest at the time), and is listed in Deep Knowledge Analytics’ top-100 AI Leaders in Drug Discovery and Advanced Healthcare.

Magdalena Otrocka, PhD
Lead Molecular Biologist

Magdalena is a seasoned biotechnologist with over two decades of experience in cell biology, assay development, and high-content screening. With a strong background in cell-based phenotypic screening, she has worked on a wide range of projects across various therapeutic areas, such as oncology, neurodegenerative disorders, and infectious diseases. 

Throughout her career, Magdalena has collaborated with professionals from diverse fields, including chemists, in-vivo biologists, and computational scientists.

As a high-throughput microscopy enthusiast, she has been responsible for establishing and managing high-content screening platforms, overseeing all aspects of high-content activities, including education and training. 

Currently, Magdalena serves as the Lead Molecular Biologist at Ardigen's Biomedical Business Unit. In this role, she focuses on delivering biologically relevant results to clients through close collaboration with data scientists and manages scientific collaborations to ensure effective teamwork and successful project outcomes.

Dawid Rymarczyk
Senior Computer Vision Specialist

Dawid, a key member of Ardigen team since 2017, is not just an AI expert but also a visionary leader. While earning his PhD in Artificial Intelligence and Computer Vision from Jagiellonian University, Kraków, he has become a specialist in analyzing high-content images, digital pathology, protein microarrays, and biomedical imaging.

Moreover, Dawid's proven project leadership has been instrumental in the success of various initiatives at Ardigen, including groundbreaking multimodal fusion projects. His unique approach to integrating chemical structures with raw images, and combining clinical data with raw imagery, sets new standards in the field of AI-driven biotech.